Your browser doesn't support javascript.
loading
Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
Singh, Sally; Maltais, François; Tombs, Lee; Fahy, William A; Vahdati-Bolouri, Mitra; Locantore, Nicholas; Riley, John H.
Affiliation
  • Singh S; Centre for Exercise and Rehabilitation Science, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK.
  • Maltais F; Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, QC, Canada.
  • Tombs L; Precise Approach Ltd, London, UK.
  • Fahy WA; GSK, Stockley Park West, Uxbridge, UK.
  • Vahdati-Bolouri M; GSK, Stockley Park West, Uxbridge, UK.
  • Locantore N; GSK, King of Prussia, PA, USA.
  • Riley JH; GSK, Stockley Park West, Uxbridge, UK.
Article in En | MEDLINE | ID: mdl-29386889
ABSTRACT

Background:

Lung hyperinflation and exercise intolerance are hallmarks of chronic obstructive pulmonary disease (COPD). However, their relationship remains uncertain. A combined analysis of two placebo-controlled, randomized studies examined the effects of the long-acting muscarinic antagonist umeclidinium (UMEC) and long-acting ß2-agonist vilanterol (VI) separately and in combination on static hyperinflation, exercise endurance time (EET), and their relationship in patients with COPD.

Methods:

Patients with moderate-to-severe stable COPD and resting functional residual capacity >120% predicted were randomized to UMEC/VI 62.5/25 µg, UMEC 62.5 µg, VI 25 µg, or placebo for 12 weeks. Inspiratory capacity (IC), residual volume (RV), total lung capacity (TLC), and EET in an endurance shuttle-walk test were measured. In this post hoc analysis, IC/TLC, RV/TLC, and IC were used as hyperinflation markers.

Results:

After 12 weeks, UMEC/VI and UMEC and VI showed significant improvements in hyperinflation versus placebo when measured by absolute change from baseline in IC/TLC (trough and 3 hours postdose [P≤0.011]). UMEC/VI showed significant improvements versus UMEC and VI in absolute changes in IC/TLC (trough and 3 hours postdose [P≤0.001]). Statistical significance for comparisons with placebo and between treatments for absolute changes in IC and percentage changes in RV/TLC followed similar patterns to those for absolute changes in IC/TLC. UMEC/VI showed significant improvements in EET versus placebo at day 2 and week 12, measured as change from baseline in seconds (P≤0.002) and as a percentage from baseline (P≤0.005). There was a lack of evidence to suggest a correlation between improvements in static hyperinflation and EET at any time point.

Conclusion:

Although the dual bronchodilator UMEC/VI demonstrated greater improvements in static hyperinflation markers than UMEC or VI and significant improvements in exercise endurance, no direct relationship was observed between static hyperinflation and exercise endurance.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinuclidines / Benzyl Alcohols / Chlorobenzenes / Exercise Tolerance / Muscarinic Antagonists / Pulmonary Disease, Chronic Obstructive / Adrenergic beta-2 Receptor Agonists / Lung Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Chron Obstruct Pulmon Dis Year: 2018 Document type: Article Affiliation country: United kingdom Publication country: NEW ZEALAND / NOVA ZELÂNDIA / NUEVA ZELANDA / NZ

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinuclidines / Benzyl Alcohols / Chlorobenzenes / Exercise Tolerance / Muscarinic Antagonists / Pulmonary Disease, Chronic Obstructive / Adrenergic beta-2 Receptor Agonists / Lung Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Chron Obstruct Pulmon Dis Year: 2018 Document type: Article Affiliation country: United kingdom Publication country: NEW ZEALAND / NOVA ZELÂNDIA / NUEVA ZELANDA / NZ